Literature DB >> 23828372

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.

Massimo Filippi1, Maria A Rocca, Stefano Bastianello, Giancarlo Comi, Paolo Gallo, Massimo Gallucci, Angelo Ghezzi, Maria Giovanna Marrosu, Giorgio Minonzio, Patrizia Pantano, Carlo Pozzilli, Gioacchino Tedeschi, Maria Trojano, Andrea Falini, Nicola De Stefano.   

Abstract

MRI is highly sensitive in detecting focal white matter lesions in multiple sclerosis (MS). For this reason, it has been formally included in the diagnostic workup of patients with clinically isolated syndromes suggestive of MS, through the definition of ad hoc sets of criteria to show disease dissemination in space and time. MRI is used in virtually all clinical trials of the disease as a surrogate measure of treatment response. Several guidelines have been published to help characterizing the imaging features on conventional MR sequences of "typical" MS lesions and work has also been performed to identify "red flags" which should alert the clinicians to exclude possible alternative conditions. Despite this, the application of the available guidelines and criteria in daily life clinical practice is still limited and varies among and within countries (including Italy) due to regulatory issues and heterogeneity of MRI facilities. It is crucial for neurologists and neuroradiologists to become familiar with these criteria to improve the quality of their diagnostic assessment. In patients with established MS, the main problem is to define standard procedures for monitoring the course of the disease and treatment response. This review aims at providing daily life guidelines to clinicians for a correct application of MRI in the workup of patients suspected of having MS as well as in the monitoring of disease evolution in those with established MS. It also offers clues for the standardization of MRI studies and relative reporting to be applied at a national level.

Entities:  

Mesh:

Year:  2013        PMID: 23828372     DOI: 10.1007/s10072-013-1485-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  28 in total

1.  Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.

Authors:  M Filippi; M A Rocca; M Calabrese; M P Sormani; F Rinaldi; P Perini; G Comi; P Gallo
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

2.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

3.  Refining response to treatment as defined by the Modified Rio Score.

Authors:  Mp Sormani; A Signori; Ml Stromillo; N De Stefano
Journal:  Mult Scler       Date:  2013-04-02       Impact factor: 6.312

4.  Scoring treatment response in patients with relapsing multiple sclerosis.

Authors:  M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano
Journal:  Mult Scler       Date:  2012-09-25       Impact factor: 6.312

5.  Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials.

Authors:  F Barkhof; M Filippi; D H Miller; P Tofts; L Kappos; A J Thompson
Journal:  J Neurol       Date:  1997-02       Impact factor: 4.849

6.  Defining interferon beta response status in multiple sclerosis patients.

Authors:  Richard A Rudick; Jar-Chi Lee; Jack Simon; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

Review 7.  Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Authors:  Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2013-05       Impact factor: 2.104

8.  Measures in the first year of therapy predict the response to interferon beta in MS.

Authors:  J Río; J Castilló; A Rovira; M Tintoré; J Sastre-Garriga; A Horga; C Nos; M Comabella; X Aymerich; X Montalbán
Journal:  Mult Scler       Date:  2009-07       Impact factor: 6.312

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  16 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

3.  MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis.

Authors:  Loredana Storelli; Maria A Rocca; Patrizia Pantano; Elisabetta Pagani; Nicola De Stefano; Gioacchino Tedeschi; Paola Zaratin; Massimo Filippi
Journal:  J Neurol       Date:  2019-08-17       Impact factor: 4.849

4.  2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Authors:  Lorenzo Gaetani; Luca Prosperini; Andrea Mancini; Paolo Eusebi; Maria Chiara Cerri; Carlo Pozzilli; Paolo Calabresi; Paola Sarchielli; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

5.  Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Authors:  Luca Prosperini; Francesco Saccà; Cinzia Cordioli; Antonio Cortese; Fabio Buttari; Simona Pontecorvo; Assunta Bianco; Serena Ruggieri; Shalom Haggiag; Vincenzo Brescia Morra; Ruggero Capra; Diego Centonze; Giancarlo Di Battista; Elisabetta Ferraro; Ada Francia; Simonetta Galgani; Claudio Gasperini; Enrico Millefiorini; Massimiliano Mirabella; Carlo Pozzilli
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

6.  The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.

Authors:  Elena Di Sabatino; Lorenzo Gaetani; Silvia Sperandei; Andrea Fiacca; Giorgio Guercini; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2021-11-24       Impact factor: 4.849

7.  No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Authors:  Luca Prosperini; Pietro Annovazzi; Laura Boffa; Maria Chiara Buscarinu; Antonio Gallo; Manuela Matta; Lucia Moiola; Luigina Musu; Paola Perini; Carlo Avolio; Valeria Barcella; Assunta Bianco; Deborah Farina; Elisabetta Ferraro; Simona Pontecorvo; Franco Granella; Luigi M E Grimaldi; Alice Laroni; Giacomo Lus; Francesco Patti; Eugenio Pucci; Matteo Pasca; Paola Sarchielli
Journal:  J Neurol       Date:  2018-09-26       Impact factor: 6.682

8.  Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.

Authors:  Caterina Veroni; Fabiana Marnetto; Letizia Granieri; Antonio Bertolotto; Clara Ballerini; Anna Maria Repice; Lucia Schirru; Giancarlo Coghe; Eleonora Cocco; Eleni Anastasiadou; Maria Puopolo; Francesca Aloisi
Journal:  J Neuroinflammation       Date:  2015-07-14       Impact factor: 8.322

Review 9.  Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Authors:  M Vågberg; M Axelsson; R Birgander; J Burman; C Cananau; Y Forslin; T Granberg; M Gunnarsson; A von Heijne; L Jönsson; V D Karrenbauer; E-M Larsson; T Lindqvist; J Lycke; L Lönn; E Mentesidou; S Müller; P Nilsson; F Piehl; A Svenningsson; M Vrethem; J Wikström
Journal:  Acta Neurol Scand       Date:  2016-08-24       Impact factor: 3.209

10.  Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.

Authors:  Marcello Moccia; Raffaele Palladino; Roberta Lanzillo; Antonio Carotenuto; Cinzia Valeria Russo; Maria Triassi; Vincenzo Brescia Morra
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.